Michael Dickinson: Results from New Study on Infections in Patients With NHL Receiving Bispecific Antibodies
Michael Dickinson/LinkedIn

Michael Dickinson: Results from New Study on Infections in Patients With NHL Receiving Bispecific Antibodies

Michael Dickinson, Professor at University of Melbourne, shared on X:

“Infections with CD3xCD20 bispecific antibodies in B-cell non-Hodgkin lymphoma: international retrospective cohort, 285 patients treated with epcoritamab, glofitamab or mosunetuzumab across four centers (incl. Peter Mac -very pleased to contribute!), median follow-up 21 months.

42% had at least one infection, 1-year cumulative incidence 36%. Grade >=3 infection in 23% of patients (1-year incidence 19%), two-thirds bacterial.

Respiratory tract the commonest site (61%). Risk persists after stopping: 1-year cumulative incidence of grade >=3 infection 10% post-treatment.

Treatment-induced hypogammaglobulinemia was the only modifiable independent predictor of grade >=3 infection (HR 3.27, 95% CI 1.59-6.72). ”

Title: Infections and their determinants in patients with non-Hodgkin lymphoma receiving bispecific T-cell antibodies: Results from an international multicenter cohort study

Authors: Zainab Shahid, Michelle Okwali, Ashlee Joseph, David Nemirovsky, Derkach Andriy, Clare Grieve, Rafaella Tringale, Reid Merryman, Aaron Zou, Silvia Ferrari, Monica Rondi, Sean Harrop, Divya Somasekharannair, Jennifer Crombie, Gilles Salles, Giuseppe Gritti, Michael Dickinson, Lorenzo Falchi.

Read the full article.

More About

Bispecific antibodies are engineered antibodies work by binding simultaneously to CD3 on T cells and CD20 on B cells, redirecting T cells to destroy malignant B cells in non-Hodgkin lymphoma.

CD3xCD20 bispecific antibodies cause on-target, off-tumor B-cell depletion (B-cell aplasia), along with T-cell exhaustion and neutropenia, because CD20 is expressed not only on malignant lymphoma cells but also on normal healthy B-cells.

Depleting normal B cells impairs the body’s ability to produce antibodies (immunoglobulins), leading to hypogammaglobulinemia and prolonged humoral immunodeficiency. This leaves patients vulnerable to bacterial and viral infections, especially in the respiratory tract, both during treatment and for months after stopping therapy while B cells slowly recover.

One-year cumulative incidence of any infection was highest with epcoritamab (47%) and mosunetuzumab (43%) compared with glofitamab. The respiratory tract was the most common site of infection (61%).

Infection risk did not end when therapy stopped; the 1-year cumulative incidence of Grade 3 or higher infections after discontinuing bispecific antibody treatment was 10%, reflecting delayed immune reconstitution.

Antimicrobial prophylaxis against HSV/VZV (96%) and PJP (86%) was widely used and associated with low rates of those complications, supporting routine prophylaxis. Overall, 30% of patients received immunoglobulin replacement therapy (IGRT).

The authors recommend heightened infection surveillance during the first 90 days, systematic IgG monitoring during and after treatment with proactive consideration of IGRT in high-risk patients (such as older patients or those with prior CAR T-cell therapy), and continued immune monitoring after stopping therapy.

You can also read:

Non-Hodgkin Lymphoma (NHL): A Practical Biological Map and Integrative Overview

Non-Hodgkin Lymphoma NHL, DLBCL